相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Metabolic and non-metabolic pathways that control cancer resistance to anthracyclines
Tania Capeloa et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2020)
Olaparib Approved for Metastatic Pancreatic Cancer
Diane S. Aschenbrenner
AMERICAN JOURNAL OF NURSING (2020)
Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia
Kshitij Verma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases
Valerio Gallotta et al.
EJSO (2019)
Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
Isabella Faraoni et al.
CANCERS (2019)
Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile
Eva Novotna et al.
ARCHIVES OF TOXICOLOGY (2018)
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
Silvia Maifrede et al.
BLOOD (2018)
AKR1C enzymes sustain therapy resistance in paediatric T-ALL
Roberta Bortolozzi et al.
BRITISH JOURNAL OF CANCER (2018)
The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-kappa B activation
Isabella Faraoni et al.
CANCER LETTERS (2018)
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
Hye Jeong Park et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer
Sina Eetezadi et al.
MOLECULAR PHARMACEUTICS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review
Trevor M. Penning
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents
Kamil Piska et al.
INVESTIGATIONAL NEW DRUGS (2017)
AR-Signaling in Human Malignancies: Prostate Cancer and Beyond
Michael T. Schweizer et al.
CANCERS (2017)
Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia
Jose J. G. Marin et al.
BLOOD REVIEWS (2016)
Inhibition of human anthracycline reductases by emodin - A possible remedy for anthracycline resistance
Jan Hintzpeter et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2016)
Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation
Shao-Qian Sun et al.
ONCOTARGET (2016)
The development of PARP inhibitors in ovarian cancer: from bench to bedside
Yvette Drew
BRITISH JOURNAL OF CANCER (2015)
Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3
Christopher M. Schaupp et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2015)
The aldo-keto reductases (AKRs): Overview
Trevor M. Penning
CHEMICO-BIOLOGICAL INTERACTIONS (2015)
Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines
Derek W. Edwardson et al.
CURRENT DRUG METABOLISM (2015)
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
Camille C. Gunderson et al.
FUTURE ONCOLOGY (2015)
Olaparib in the management of ovarian cancer
Kristin Bixel et al.
PHARMACOGENOMICS & PERSONALIZED MEDICINE (2015)
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
G. Del Conte et al.
BRITISH JOURNAL OF CANCER (2014)
Carbonyl reduction pathways in drug metabolism
Petra Malatkova et al.
DRUG METABOLISM REVIEWS (2014)
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
X. Wei Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3
Jakub Hofman et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2014)
AKR1C3 as a target in castrate resistant prostate cancer
Adegoke O. Adeniji et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2013)
Role of carbonyl reducing enzymes in the phase I biotransformation of the non-steroidal anti-inflammatory drug nabumetone in vitro
Lucie Skarydova et al.
XENOBIOTICA (2013)
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
Mikkel Krogh-Madsen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia
Savitha Varatharajan et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
ZINC: A Free Tool to Discover Chemistry for Biology
John J. Irwin et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
Aldo-keto reductase 1B10 and its role in proliferation capacity of drug-resistant cancers
Toshiyuki Matsunaga et al.
FRONTIERS IN PHARMACOLOGY (2012)
Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights
Michael C. Byrns et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2011)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Software News and Update AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading
Oleg Trott et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2010)
Naturally Occurring Variants of Human Aldo-Keto Reductases with Reduced In Vitro Metabolism of Daunorubicin and Doxorubicin
Onkar S. Bains et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Steroid Hormone Transforming Aldo-Keto Reductases and Cancer
Trevor M. Penning et al.
STEROID ENZYMES AND CANCER (2009)
AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility
Garrett M. Morris et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2009)
The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: Implications for leukemogenesis
Lane Birtwistle et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver
Nina Kassner et al.
DRUG METABOLISM AND DISPOSITION (2008)
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Darren J. Burgess et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Sven Rottenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3
Romana Novotna et al.
TOXICOLOGY LETTERS (2008)
Role of anthracyclines in the era of targeted therapy
Hernan Cortes-Funes et al.
CARDIOVASCULAR TOXICOLOGY (2007)
Crystal structures of prostaglandin D2 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin
AL Lovering et al.
CANCER RESEARCH (2004)
分享论文
